PaccMann$^{RL}$ on SARS-CoV-2: Designing antiviral candidates with conditional generative models

• URL: http://arxiv.org/abs/2005.13285v3
• Date: Mon, 6 Jul 2020 14:44:02 GMT
• Title: PaccMann$^{RL}$ on SARS-CoV-2: Designing antiviral candidates with conditional generative models
• Authors: Jannis Born, Matteo Manica, Joris Cadow, Greta Markert, Nil Adell Mill, Modestas Filipavicius, Mar\'ia Rodr\'iguez Mart\'inez
• Abstract summary: With the fast development of COVID-19 into a global pandemic, scientists around the globe are desperately searching for effective antiviral therapeutic agents. We propose a deep learning framework for conditional de novo design of antiviral candidate drugs tailored against given protein targets.
• Score: 2.0750380105212116
• License: http://creativecommons.org/licenses/by/4.0/
• Abstract: With the fast development of COVID-19 into a global pandemic, scientists around the globe are desperately searching for effective antiviral therapeutic agents. Bridging systems biology and drug discovery, we propose a deep learning framework for conditional de novo design of antiviral candidate drugs tailored against given protein targets. First, we train a multimodal ligand--protein binding affinity model on predicting affinities of antiviral compounds to target proteins and couple this model with pharmacological toxicity predictors. Exploiting this multi-objective as a reward function of a conditional molecular generator (consisting of two VAEs), we showcase a framework that navigates the chemical space toward regions with more antiviral molecules. Specifically, we explore a challenging setting of generating ligands against unseen protein targets by performing a leave-one-out-cross-validation on 41 SARS-CoV-2-related target proteins. Using deep RL, it is demonstrated that in 35 out of 41 cases, the generation is biased towards sampling more binding ligands, with an average increase of 83% comparing to an unbiased VAE. We present a case-study on a potential Envelope-protein inhibitor and perform a synthetic accessibility assessment of the best generated molecules is performed that resembles a viable roadmap towards a rapid in-vitro evaluation of potential SARS-CoV-2 inhibitors.

Related papers

• Dense Feature Memory Augmented Transformers for COVID-19 Vaccination Search Classification [60.49594822215981]
  This paper presents a classification model for detecting COVID-19 vaccination related search queries. We propose a novel approach of considering dense features as memory tokens that the model can attend to. We show that this new modeling approach enables a significant improvement to the Vaccine Search Insights (VSI) task.
  arXiv  Detail & Related papers  (2022-12-16T13:57:41Z)
• Accelerating Inhibitor Discovery for Multiple SARS-CoV-2 Targets with a Single, Sequence-Guided Deep Generative Framework [47.14853881703749]
  We demonstrate the broad utility of a single deep generative framework toward discovering novel drug-like inhibitor molecules. To perform target-aware design, the framework employs a target sequence-conditioned sampling of novel molecules from a generative model. The most potent spike RBD inhibitor also emerged as a rare non-covalent antiviral with broad-spectrum activity against several SARS-CoV-2 variants.
  arXiv  Detail & Related papers  (2022-04-19T17:59:46Z)
• Improved Drug-target Interaction Prediction with Intermolecular Graph Transformer [98.8319016075089]
  We propose a novel approach to model intermolecular information with a three-way Transformer-based architecture. Intermolecular Graph Transformer (IGT) outperforms state-of-the-art approaches by 9.1% and 20.5% over the second best for binding activity and binding pose prediction respectively. IGT exhibits promising drug screening ability against SARS-CoV-2 by identifying 83.1% active drugs that have been validated by wet-lab experiments with near-native predicted binding poses.
  arXiv  Detail & Related papers  (2021-10-14T13:28:02Z)
• Evening the Score: Targeting SARS-CoV-2 Protease Inhibition in Graph Generative Models for Therapeutic Candidates [11.853524110656991]
  We look at the therapeutic design of novel drug candidates targeting SARS-CoV-2 viral proteins. We use an autoencoder that generates molecules with similar structures to a dataset of drugs with anti-SARS activity. During generation, we explore optimization toward several design targets to balance druglikeness, synthetic accessability, and anti-SARS activity.
  arXiv  Detail & Related papers  (2021-05-07T18:39:25Z)
• High-Throughput Virtual Screening of Small Molecule Inhibitors for SARS-CoV-2 Protein Targets with Deep Fusion Models [3.8075853084146023]
  Over 500 million small molecules were screened against four protein structures from the novel coronavirus (SARS-CoV-2), which causes COVID-19. Three enhancements to Deep Fusion were made in order to evaluate more than 5 billion docked poses on SARS-CoV-2 protein targets.
  arXiv  Detail & Related papers  (2021-04-09T18:18:26Z)
• Designing a Prospective COVID-19 Therapeutic with Reinforcement Learning [50.57291257437373]
  SARS-CoV-2 pandemic has created a global race for a cure. One approach focuses on designing a novel variant of the human angiotensin-converting enzyme 2 (ACE2) We formulate a novel protein design framework as a reinforcement learning problem.
  arXiv  Detail & Related papers  (2020-12-03T07:35:38Z)
• Accelerating Antimicrobial Discovery with Controllable Deep Generative Models and Molecular Dynamics [109.70543391923344]
  CLaSS (Controlled Latent attribute Space Sampling) is an efficient computational method for attribute-controlled generation of molecules. We screen the generated molecules for additional key attributes by using deep learning classifiers in conjunction with novel features derived from atomistic simulations. The proposed approach is demonstrated for designing non-toxic antimicrobial peptides (AMPs) with strong broad-spectrum potency.
  arXiv  Detail & Related papers  (2020-05-22T15:57:58Z)
• Evolutionary Multi-Objective Design of SARS-CoV-2 Protease Inhibitor Candidates [0.0]
  We propose an evolutionary multi-objective algorithm (EMOA) to design potential protease inhibitors for SARS-CoV-2's main protease. Based on the SELFIES representation the EMOA maximizes the binding of candidate to the protein using the docking tool QuickVina 2. The experimental part analyzes the evolutionary process and discusses the inhibitor candidates.
  arXiv  Detail & Related papers  (2020-05-06T09:15:20Z)
• CogMol: Target-Specific and Selective Drug Design for COVID-19 Using Deep Generative Models [74.58583689523999]
  We propose an end-to-end framework, named CogMol, for designing new drug-like small molecules targeting novel viral proteins. CogMol combines adaptive pre-training of a molecular SMILES Variational Autoencoder (VAE) and an efficient multi-attribute controlled sampling scheme. CogMol handles multi-constraint design of synthesizable, low-toxic, drug-like molecules with high target specificity and selectivity.
  arXiv  Detail & Related papers  (2020-04-02T18:17:20Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.